)
Sun Pharmaceuticals Industries has dipped 6% to Rs 808 on National Stock Exchange on reports that the company’s manufacturing facility in Halol (Gujarat) is undergoing a surprise inspection by the US Food and Drug Administration (US FDA).
“The move may have been triggered by a number of recent recalls from the plant,” the Business Standard report suggests quoting unnamed sources.
In May, Sun Pharma's another manufacturing facility in Karkhadi, also in Gujarat, had received a warning letter from the US FDA after investigators identified violations of current good manufacturing practice and regulations for finished pharmaceuticals, added report.
The stock opened at Rs 850 and has seen a combined 1.28 million shares changing hands on the counter in early morning deals on NSE and BSE.
“The move may have been triggered by a number of recent recalls from the plant,” the Business Standard report suggests quoting unnamed sources.
In May, Sun Pharma's another manufacturing facility in Karkhadi, also in Gujarat, had received a warning letter from the US FDA after investigators identified violations of current good manufacturing practice and regulations for finished pharmaceuticals, added report.
The stock opened at Rs 850 and has seen a combined 1.28 million shares changing hands on the counter in early morning deals on NSE and BSE.
